(NASDAQ: MNMD) Mind Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.7%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.75%.
Mind Medicine's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast MNMD's revenue for 2027 to be $18,294,467,829, with the lowest MNMD revenue forecast at $6,301,142,384, and the highest MNMD revenue forecast at $30,287,793,274. On average, 3 Wall Street analysts forecast MNMD's revenue for 2028 to be $34,379,002,628, with the lowest MNMD revenue forecast at $6,369,140,324, and the highest MNMD revenue forecast at $71,699,293,901.
In 2029, MNMD is forecast to generate $89,305,093,711 in revenue, with the lowest revenue forecast at $61,311,475,359 and the highest revenue forecast at $117,298,712,063.